SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism · 14.07.2023 · 108 (8) · 2134-2140
DOI: 10.1210/clinem/dgad113 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.02.2023. Verfasst von Pradip Mukhopadhyay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Myocardial Infarction, Stroke. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Themen: Diabetes mellitus, Schlaganfall
Abstract (Originalsprache)
Background
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have recently been recommended as preferred agents for management of hyperglycemia in type 2 diabetes, primarily based on their ability to reduce a composite of major cardiovascular adverse events (3-point major adverse cardiovascular events [MACE]), predominantly by reducing cardiovascular death. However, reduction of the individual components, myocardial infarction (MI), or stroke (fatal and nonfatal) events have not been well explored.
Methods
In this meta-analysis, we included data available from cardiovascular outcome trials only, which were event-driven, randomized, and placebo-controlled. Pooled efficacy outcomes included Mantel Haenszel (MH) risk ratio using fixed model (with 95% CI) for fatal and nonfatal MI, stroke, and total MI and stroke.
Findings
Data from 4 eligible trials included 42,568 subjects. Total MACE, MI, and stroke were reported in 4176, 2157, and 1288 subjects, respectively. SGLT2is did not significantly reduce either MI or stroke individually or in totality. The MH risk ratio (95% CI) for fatal and nonfatal MI and stroke with different SGLT2is was found to be 0.93 (95% CI, 0.85-1.01) and 1.00 (95% CI, 0.89-1.11), respectively. For total atherosclerotic cardiovascular disease (ASCVD) events, MH risk ratio (95% CI) was 0.95 (95% CI, 0.89-1.02). For all nonfatal ASCVD (combined nonfatal MI and nonfatal stroke), MH risk ratio (95% CI) was 0.94 (95% CI, 0.88-1.02).
Interpretation
SGLT2is reduce MACE without any discernable significant reduction of the incidence of MI or stroke (fatal and nonfatal), probably implicating mechanisms unrelated to anti-atherogenic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India.
- Department of Endocrinology, KPC Medical College & Hospital, 1F, Raja Subodh Chandra Mallick Road, Jadavpur, Kolkata, West Bengal 700032, India.
- Department of Endocrinology, Apollo Gleneagles Hospital, 58 Canal Circular Road, Kolkata, West Bengal 700054.
ORCID-Profile: Pradip Mukhopadhyay, Sujoy Ghosh
Zitieren
APA
Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. (2023). SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 108(8), 2134-2140. https://doi.org/10.1210/clinem/dgad113
Vancouver
Mukhopadhyay P, Sanyal D, Chatterjee P, Pandit K, Ghosh S. SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):2134-2140. doi:10.1210/clinem/dgad113
BibTeX
@article{Mukhopadhyay2023,
author = {Mukhopadhyay, Pradip and Sanyal, Debmalya and Chatterjee, Purushottam and Pandit, Kaushik and Ghosh, Sujoy},
title = {SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {8},
pages = {2134--2140},
doi = {10.1210/clinem/dgad113}
}
EUVIMED